Mount Sinai Researcher Receives NIH Award to Study Immune Responses of Patients With Inflammatory Skin Diseases in the Setting of COVID-19 Infection

The study will aim to understand whether systemic medications and biologics, such as dupilumab—a monoclonal antibody that binds to an inflammatory molecule, IL-4 receptor alfa, and inhibits the inflammatory response that leads to rashes and itching from atopic dermatitis/eczema—may have a positive or negative impact on COVID-19 responses in patients who have the disease.

Read more

Biomedical researchers get closer to why eczema happens

A new study from Binghamton University, State University of New York may help to peel back the layers of unhealthy skin — at least metaphorically speaking — and get closer to a cure.

Read more

Painless Tape Strips Used to Detect Molecular Changes in Skin of Children with Eczema

In a study using non-invasive tape strips in young children with eczema (or atopic dermatitis), researchers found many molecular signs of immune dysfunction and skin changes that relate to disease activity. These signs (or biomarkers) were present even before eczema was visible and can be used to track disease activity over time. With more research, these biomarkers also may help predict response to medicine and development of conditions associated with eczema, such as asthma, other allergies, infections and even attention deficit hyperactivity disorder (ADHD). Findings were published in JAMA Dermatology.

Read more